Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes

Type 1 Diabetes Mellitus Clinical Trial

Official title:

A Phase I/II, 3-Arm, Open Label, Single Centre Study to Investigate the Safety and Effect of Oral GABA Therapy on Beta-Cell Regeneration in Type 1-diabetes Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03635437
• Other study ID #: Regenerate-1 (G/P2/18/1)
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: September 5, 2018
• Est. completion date: September 27, 2022

Study information

• Verified date: November 2022
• Source: Uppsala University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main goal of this study is to find a reasonably safe and tolerable treatment for adult patients with type 1-diabetes and that regain some of the endogenous insulin secretion, improve the patients' quality of life (QoL) and reduce the risk of both short- and long-term complications. The hypothesis tested is that oral GABA treatment with the newly developed compound Remygen will be safe and induce regain of some endogenous insulin secretion in adult patients with type 1-diabetes diagnosis for more than five years. The first part of the study will include 6 patients and be performed as a Safety and Dose Escalation study in three steps. The main study is a three-arm, open label, single center, clinical trial. Eligible patients will be randomized into one of three active treatment arms to receive oral GABA treatment for 6 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: September 27, 2022
• Est. primary completion date: September 27, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Informed consent given by patients according to national regulations

2. Type 1 diabetes diagnosed = 5 years at the time of screening

3. Must have been diagnosed with Type 1-diabetes before the age of 25

4. Age =18 and =50

5. Fasting c-peptide levels should be in the range from not detectable levels up to <0.12 nmol/L

6. For males of childbearing potential adequate contraception is as follows:

1. condom (male)

2. abstinence from heterosexual intercourse

3. female partner using contraception as below listed:

• oral (except low-dose gestagen (lynestrenol and norethisterone)), injectable, or implanted hormonal contraceptives

• combined (estrogen and progestogen containing)

• oral, intravaginal or transdermal progesterone hormonal contraception associated with inhibition of ovulation

• intrauterine device

• intrauterine hormone-releasing system (for example, progestin-releasing coil)

• bilateral tubal occlusion

Exclusion Criteria:

1. Females of child-bearing potential

2. Previous or current treatment with immunosuppressant therapy (although topical and inhalation steroids are accepted)

3. Treatment with any oral or injected anti-diabetic medications other than insulin

4. Patients on medications which may disturb GABA action, such as Baclofen, Valium, Acamprosate, Neurontin, or Lyrica

5. HbA1c > 90 mmol/mol

6. eGFR <60 ml/min

7. Increased plasma concentrations of alanine aminotransferase (>0.75 µkatl/l for females or >1.1 µkat/l for males) and/or aspartate aminotransferase (>0.60 µkat/l for females or >0.75µkat/l for males).

8. Known cancer disease

9. Known sleeping apnea or pulmonary disorder with carbon dioxide rentention in blood

10. Previous history of pancreatitis or other exocrine pancreatic disorder

11. A history of epilepsy, myasthenia gravis, head trauma or cerebrovascular accident, or clinical features of continuous motor unit activity in proximal muscles

12. A history of alcohol or drug abuse

13. A significant illness other than diabetes within 2 weeks prior to first dosing

14. Known human immunodeficiency virus (HIV) or hepatitis

15. Females who are breastfeeding

16. Males not willing to use adequate contraception during the study period.

17. Known hypersensitivity agains benzodiazepins or any excipients of study drugs

18. Participation in other clinical trials with a new chemical entity within 3 months or 5 half-lives of the new chemical entity, whatever longest.

19. Inability or unwillingness to comply with the provisions of this protocol

20. Deemed by the investigator not being able to follow instructions and/or follow the study protocol or other reasons that, at the investigator's discretion, could affect the subject's current clinical condition during study procedures.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type 1 Diabetes Mellitus

Intervention

Drug:
• Gamma-Aminobutyric Acid (GABA)
Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
• Alprazolam
Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.

Locations

Country	Name	City	State
Sweden	Uppsala University Hospital	Uppsala

Sponsors (2)

Lead Sponsor	Collaborator
Per-Ola Carlsson	Diamyd Medical AB

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse events possibly or probably related to GABA treatment	To evaluate the acute and long-term safety of oral GABA treatment. The endpoint will investigate number of adverse events possibly or probably related to GABA treatment.	6 months
Secondary	Difference in C-peptide response to mixed meal tolerance test before and directly after treatment	Difference in C-peptide (Area under the curve 0-120 min) during a mixed meal tolerance test between baseline and after 6 months of oral GABA treatment	6 months
Secondary	Difference in C-peptide response to mixed meal tolerance test during and after treatment	Difference in C-peptide (Area under the curve 0-120 min) during a mixed meal tolerance test between baseline and after 3 and and 6 months of treatment and between baseline and the follow-up visit	7 months
Secondary	Difference in maximum stimulated C-peptide to mixed meal tolerance test during and after treatment	Difference in maximum stimulated C-peptide during a mixed meal tolerance test between baseline and after 3 and 6 months of treatment and between baseline and the follow-up visit.	7 months
Secondary	Difference in C-peptide response to mixed meal tolerance test during and after treatment between treatment groups	Difference in C-peptide (Area under the curve 0-120 min) during a mixed meal tolerance test between treatment group 1 and 2 and after 3 and 6 months of treatment and between baseline and the follow-up visit	7 months
Secondary	Difference in glucagon response during a hypoglycemic clamp before and after treatment	Difference in glucagon (area under the curve) during a hypoglycemic clamp between baseline and 6 months of treatment	7 months
Secondary	Difference in glucagon response during a hypoglycemic clamp between treatment groups before and after treatment	Difference in glucagon (area under the curve) during a hypoglycemic clamp between treatment group 1 and 2 between baseline and 6 months of treatment	7 months
Secondary	Change in HbA1c by treatment	Change in HbA1c between 0,3 and 6 months of treatment and at the follow-up one month later.	7 months
Secondary	Change in exogenous insulin consumption by treatment	Change in exogenous insulin consumption between 0,3 and 6 months of treatment and at the follow-up one month later.	7 months
Secondary	Change in fasting C-peptide by treatment	Change in fasting C-peptide levels between 0,3 and 6 months of treatment and at the follow-up one month later.	7 months
Secondary	Change in variables that indicate effects on immune system	Change by treatment in variables that indicate effects on the immune system such as serum autoantibodies to GAD65 and islet antigen-2, and immune cells	7 months
Secondary	Change in GABA plasma levels	Analysis of GABA plasma levels after 0, 3 and 6 months of treatment and at the follow-up visit one month later.	7 months
Secondary	Change in diabetes treatment satisfaction questionnaire	Measurements of patient diabetes treatment satisfaction by questionnaire during study. Each of eight questions have a 7-graded scale from 0-6. 48 points are therefore maximal treatment satisfaction and comparisons will be made to score before treatment start.	7 months